Company / Shareholders' Equity
Abbott Laboratories Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$52.1B
FY2025
5-year range
$35.8B / $52.1B
FY2021-FY2025
Trend
+9.4%
vs FY2024
Sector context
#5 of 161
Health Care
What the data says
Among 161 Health Care companies, Abbott Laboratories is in the top 3% for shareholders' equity. Shareholders' Equity has increased for 7 consecutive years, from $30.5B in FY2018 to $52.1B in FY2025.
Based on SEC 10-K filings.
$52.1B in FY2025 with a 5-year CAGR of +9.7%. Top quartile in the Health Care sector.
Improved from $38.6B to $52.1B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +12.4%
- 5-Year CAGR
- +9.7%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 161This company $52.1B Sector average $5.1B
▼
+929.5% above sector average
Key checks
Key Insights
- Abbott Laboratories's shareholders' equity has grown for 7 consecutive years.
- 5-year CAGR of +9.7%, indicating consistent growth.
- In FY2025, shareholders' equity increased 9.4% year-over-year.
- Ranks #5 out of 161 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $52.1B | +9.4% |
| FY2024 | $47.7B | +23.5% |
| FY2023 | $38.6B | +5.2% |
| FY2022 | $36.7B | +2.5% |
| FY2021 | $35.8B | +9.2% |
| FY2020 | $32.8B | +5.5% |
| FY2019 | $31.1B | +1.8% |
| FY2018 | $30.5B | -1.2% |
| FY2017 | $30.9B | +50.4% |
| FY2016 | $20.5B | -3.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026